Global Pan-cancer Genetic Testing Market Growth (Status and Outlook) 2026-2032
The global Pan-cancer Genetic Testing market size is predicted to grow from US$ 6143 million in 2025 to US$ 15230 million in 2032; it is expected to grow at a CAGR of 13.9% from 2026 to 2032.
Pan-cancer Genetic Testing refers to clinical diagnostic and precision oncology solutions that use targeted next-generation sequencing, whole-exome sequencing, whole-transcriptome sequencing, or multimodal molecular analysis to profile cancer-related genomic alterations and biomarkers across multiple solid tumors or hematologic malignancies. Major targets include single nucleotide variants, insertions and deletions, copy number alterations, gene fusions and rearrangements, as well as genomic signatures such as tumor mutational burden, microsatellite instability, and homologous recombination deficiency. Commercial offerings include centralized laboratory testing services, tissue and liquid biopsy assay kits, integrated testing systems, and associated bioinformatics solutions. These tests are mainly used for targeted therapy selection, immunotherapy assessment, clinical trial matching, molecular classification, and resistance analysis. Key upstream inputs include specimen collection components, nucleic acid extraction and library preparation reagents, capture probes, sequencing flow cells, quality controls, sequencing platforms, bioinformatics algorithms, and genomic databases. Major downstream customers include hospitals, cancer centers, independent clinical laboratories, pathology laboratories, pharmaceutical and biotechnology companies, and clinical research organizations. The estimated industry gross margin is generally approximately 50%–70%.
The global Pan-cancer Genetic Testing market is shifting from sequential single-gene and tumor-specific testing toward comprehensive genomic profiling. As the number of actionable alterations, immunotherapy biomarkers, and tumor-agnostic treatment indications increases, sequential testing has become less efficient because of tissue consumption, longer turnaround times, and cumulative cost. Large genomic panels can evaluate multiple variant classes and genomic signatures in a single test and are therefore gaining adoption among patients with advanced solid tumors or limited standard treatment options. North America is primarily characterized by centralized reference laboratory services, while Europe and Japan rely more heavily on combinations of approved products and designated hospital networks. China has developed a mixed structure that includes centralized testing services, hospital-based laboratories, and locally manufactured standardized assay kits.
Tissue-based testing remains the foundation of comprehensive genomic profiling, but liquid biopsy is becoming an important complementary option for patients with insufficient tissue, high biopsy risk, or a need for faster results. Testing scope is expanding from targeted panels containing several hundred genes toward integrated DNA and RNA analysis, matched tumor-normal sequencing, whole-exome sequencing, and whole-transcriptome sequencing. RNA analysis can improve the detection of gene fusions and abnormal splicing events, while matched-normal analysis can distinguish somatic alterations from germline variants and clonal hematopoiesis signals. Future differentiation will depend increasingly on analytical performance in low-tumor-content samples, fusion detection, turnaround time, the strength of clinical evidence, and the actionability of report interpretation rather than on gene count alone.
Market growth is supported by the expansion of precision oncology, increasing numbers of tumor-agnostic targeted and immunotherapy indications, stronger guideline recommendations, and broader availability of hospital NGS infrastructure. Drug development programs increasingly stratify patients according to shared molecular alterations across different tumor types rather than according to the organ of origin alone. Pharmaceutical demand for companion diagnostic development, clinical trial recruitment, biomarker strategy, and real-world evidence also provides testing companies with revenue opportunities beyond routine patient testing. As sequencing costs decline, workflows become more automated, and reimbursement coverage improves, pan-cancer testing is expected to extend from late-stage and rare cases toward earlier treatment stages and a broader patient population.
The industry nevertheless faces constraints related to specimen quality, testing cost, reimbursement, and the clinical conversion of genomic findings. Differences in gene coverage, sequencing depth, variant thresholds, and reporting rules may lead to inconsistent results across laboratories. Some patients have potentially actionable alterations but cannot access the matched treatment because of regulatory indications, drug availability, or the location of relevant clinical trials. Competition between hospital-developed assays and centralized laboratory services may place pressure on pricing and lead to duplicated infrastructure investment. Future competitive advantage will depend on regulatory approvals, companion diagnostic partnerships, liquid biopsy performance, interpretation capabilities, reimbursement access, and evidence of clinical utility, while companies must also address incidental germline findings, informed consent, and the security of genomic data.
LPI (LP Information)' newest research report, the “Pan-cancer Genetic Testing Industry Forecast” looks at past sales and reviews total world Pan-cancer Genetic Testing sales in 2025, providing a comprehensive analysis by region and market sector of projected Pan-cancer Genetic Testing sales for 2026 through 2032. With Pan-cancer Genetic Testing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Pan-cancer Genetic Testing industry.
This Insight Report provides a comprehensive analysis of the global Pan-cancer Genetic Testing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Pan-cancer Genetic Testing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Pan-cancer Genetic Testing market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Pan-cancer Genetic Testing and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Pan-cancer Genetic Testing.
This report presents a comprehensive overview, market shares, and growth opportunities of Pan-cancer Genetic Testing market by product type, application, key players and key regions and countries.
Pan-cancer Genetic Testing refers to clinical diagnostic and precision oncology solutions that use targeted next-generation sequencing, whole-exome sequencing, whole-transcriptome sequencing, or multimodal molecular analysis to profile cancer-related genomic alterations and biomarkers across multiple solid tumors or hematologic malignancies. Major targets include single nucleotide variants, insertions and deletions, copy number alterations, gene fusions and rearrangements, as well as genomic signatures such as tumor mutational burden, microsatellite instability, and homologous recombination deficiency. Commercial offerings include centralized laboratory testing services, tissue and liquid biopsy assay kits, integrated testing systems, and associated bioinformatics solutions. These tests are mainly used for targeted therapy selection, immunotherapy assessment, clinical trial matching, molecular classification, and resistance analysis. Key upstream inputs include specimen collection components, nucleic acid extraction and library preparation reagents, capture probes, sequencing flow cells, quality controls, sequencing platforms, bioinformatics algorithms, and genomic databases. Major downstream customers include hospitals, cancer centers, independent clinical laboratories, pathology laboratories, pharmaceutical and biotechnology companies, and clinical research organizations. The estimated industry gross margin is generally approximately 50%–70%.
The global Pan-cancer Genetic Testing market is shifting from sequential single-gene and tumor-specific testing toward comprehensive genomic profiling. As the number of actionable alterations, immunotherapy biomarkers, and tumor-agnostic treatment indications increases, sequential testing has become less efficient because of tissue consumption, longer turnaround times, and cumulative cost. Large genomic panels can evaluate multiple variant classes and genomic signatures in a single test and are therefore gaining adoption among patients with advanced solid tumors or limited standard treatment options. North America is primarily characterized by centralized reference laboratory services, while Europe and Japan rely more heavily on combinations of approved products and designated hospital networks. China has developed a mixed structure that includes centralized testing services, hospital-based laboratories, and locally manufactured standardized assay kits.
Tissue-based testing remains the foundation of comprehensive genomic profiling, but liquid biopsy is becoming an important complementary option for patients with insufficient tissue, high biopsy risk, or a need for faster results. Testing scope is expanding from targeted panels containing several hundred genes toward integrated DNA and RNA analysis, matched tumor-normal sequencing, whole-exome sequencing, and whole-transcriptome sequencing. RNA analysis can improve the detection of gene fusions and abnormal splicing events, while matched-normal analysis can distinguish somatic alterations from germline variants and clonal hematopoiesis signals. Future differentiation will depend increasingly on analytical performance in low-tumor-content samples, fusion detection, turnaround time, the strength of clinical evidence, and the actionability of report interpretation rather than on gene count alone.
Market growth is supported by the expansion of precision oncology, increasing numbers of tumor-agnostic targeted and immunotherapy indications, stronger guideline recommendations, and broader availability of hospital NGS infrastructure. Drug development programs increasingly stratify patients according to shared molecular alterations across different tumor types rather than according to the organ of origin alone. Pharmaceutical demand for companion diagnostic development, clinical trial recruitment, biomarker strategy, and real-world evidence also provides testing companies with revenue opportunities beyond routine patient testing. As sequencing costs decline, workflows become more automated, and reimbursement coverage improves, pan-cancer testing is expected to extend from late-stage and rare cases toward earlier treatment stages and a broader patient population.
The industry nevertheless faces constraints related to specimen quality, testing cost, reimbursement, and the clinical conversion of genomic findings. Differences in gene coverage, sequencing depth, variant thresholds, and reporting rules may lead to inconsistent results across laboratories. Some patients have potentially actionable alterations but cannot access the matched treatment because of regulatory indications, drug availability, or the location of relevant clinical trials. Competition between hospital-developed assays and centralized laboratory services may place pressure on pricing and lead to duplicated infrastructure investment. Future competitive advantage will depend on regulatory approvals, companion diagnostic partnerships, liquid biopsy performance, interpretation capabilities, reimbursement access, and evidence of clinical utility, while companies must also address incidental germline findings, informed consent, and the security of genomic data.
LPI (LP Information)' newest research report, the “Pan-cancer Genetic Testing Industry Forecast” looks at past sales and reviews total world Pan-cancer Genetic Testing sales in 2025, providing a comprehensive analysis by region and market sector of projected Pan-cancer Genetic Testing sales for 2026 through 2032. With Pan-cancer Genetic Testing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Pan-cancer Genetic Testing industry.
This Insight Report provides a comprehensive analysis of the global Pan-cancer Genetic Testing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Pan-cancer Genetic Testing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Pan-cancer Genetic Testing market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Pan-cancer Genetic Testing and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Pan-cancer Genetic Testing.
This report presents a comprehensive overview, market shares, and growth opportunities of Pan-cancer Genetic Testing market by product type, application, key players and key regions and countries.
Segmentation by Type:
- Tissue-based Testing
- Liquid Biopsy Testing
- Other
Segmentation by Testing Scope:
- Medium Panels (50–199 Genes)
- Large Panels (200–599 Genes)
- Extended Panels (600–999 Genes)
- Other
Segmentation by Technology:
- Targeted NGS
- Whole-exome Sequencing
- Whole-transcriptome Sequencing
- Other
Segmentation by Application:
- Hospitals and Cancer Centers
- Independent Clinical Laboratories
- Other
This report also splits the market by region:
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Roche
- Guardant Health
- Caris Life Sciences
- Tempus AI
- Labcorp
- NeoGenomics
- Exact Sciences
- Personalis
- Illumina
- Thermo Fisher Scientific
- QIAGEN
- Agilent Technologies
- SOPHiA GENETICS
- Sysmex
- Burning Rock Biotech
- Genetron Health
- Geneseeq
- BGI Genomics
- Amoy Diagnostics
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Pan-cancer Genetic Testing Market Size (2021-2032)
2.1.2 Pan-cancer Genetic Testing Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Pan-cancer Genetic Testing by Country/Region (2021, 2025 & 2032)
2.2 Pan-cancer Genetic Testing Segment by Type
2.2.1 Tissue-based Testing
2.2.2 Liquid Biopsy Testing
2.2.3 Other
2.2.4 Pan-cancer Genetic Testing Market Size by Type
2.2.4.1 Pan-cancer Genetic Testing Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.4.2 Global Pan-cancer Genetic Testing Market Size Market Share by Type (2021-2026)
2.3 Pan-cancer Genetic Testing Segment by Testing Scope
2.3.1 Medium Panels (50–199 Genes)
2.3.2 Large Panels (200–599 Genes)
2.3.3 Extended Panels (600–999 Genes)
2.3.4 Other
2.3.5 Pan-cancer Genetic Testing Market Size by Testing Scope
2.3.5.1 Pan-cancer Genetic Testing Market Size CAGR by Testing Scope (2021 VS 2025 VS 2032)
2.3.5.2 Global Pan-cancer Genetic Testing Market Size Market Share by Testing Scope (2021-2026)
2.4 Pan-cancer Genetic Testing Segment by Technology
2.4.1 Targeted NGS
2.4.2 Whole-exome Sequencing
2.4.3 Whole-transcriptome Sequencing
2.4.4 Other
2.4.5 Pan-cancer Genetic Testing Market Size by Technology
2.4.5.1 Pan-cancer Genetic Testing Market Size CAGR by Technology (2021 VS 2025 VS 2032)
2.4.5.2 Global Pan-cancer Genetic Testing Market Size Market Share by Technology (2021-2026)
2.5 Pan-cancer Genetic Testing Segment by Application
2.5.1 Hospitals and Cancer Centers
2.5.2 Independent Clinical Laboratories
2.5.3 Other
2.5.4 Pan-cancer Genetic Testing Market Size by Application
2.5.4.1 Pan-cancer Genetic Testing Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.4.2 Global Pan-cancer Genetic Testing Market Size Market Share by Application (2021-2026)
3 PAN-CANCER GENETIC TESTING MARKET SIZE BY PLAYER
3.1 Pan-cancer Genetic Testing Market Size Market Share by Player
3.1.1 Global Pan-cancer Genetic Testing Revenue by Player (2021-2026)
3.1.2 Global Pan-cancer Genetic Testing Revenue Market Share by Player (2021-2026)
3.2 Global Pan-cancer Genetic Testing Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 PAN-CANCER GENETIC TESTING BY REGION
4.1 Pan-cancer Genetic Testing Market Size by Region (2021-2026)
4.2 Global Pan-cancer Genetic Testing Annual Revenue by Country/Region (2021-2026)
4.3 Americas Pan-cancer Genetic Testing Market Size Growth (2021-2026)
4.4 APAC Pan-cancer Genetic Testing Market Size Growth (2021-2026)
4.5 Europe Pan-cancer Genetic Testing Market Size Growth (2021-2026)
4.6 Middle East & Africa Pan-cancer Genetic Testing Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Pan-cancer Genetic Testing Market Size by Country (2021-2026)
5.2 Americas Pan-cancer Genetic Testing Market Size by Type (2021-2026)
5.3 Americas Pan-cancer Genetic Testing Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Pan-cancer Genetic Testing Market Size by Region (2021-2026)
6.2 APAC Pan-cancer Genetic Testing Market Size by Type (2021-2026)
6.3 APAC Pan-cancer Genetic Testing Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Pan-cancer Genetic Testing Market Size by Country (2021-2026)
7.2 Europe Pan-cancer Genetic Testing Market Size by Type (2021-2026)
7.3 Europe Pan-cancer Genetic Testing Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Pan-cancer Genetic Testing by Region (2021-2026)
8.2 Middle East & Africa Pan-cancer Genetic Testing Market Size by Type (2021-2026)
8.3 Middle East & Africa Pan-cancer Genetic Testing Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL PAN-CANCER GENETIC TESTING MARKET FORECAST
10.1 Global Pan-cancer Genetic Testing Forecast by Region (2027-2032)
10.1.1 Global Pan-cancer Genetic Testing Forecast by Region (2027-2032)
10.1.2 Americas Pan-cancer Genetic Testing Forecast
10.1.3 APAC Pan-cancer Genetic Testing Forecast
10.1.4 Europe Pan-cancer Genetic Testing Forecast
10.1.5 Middle East & Africa Pan-cancer Genetic Testing Forecast
10.2 Americas Pan-cancer Genetic Testing Forecast by Country (2027-2032)
10.2.1 United States Market Pan-cancer Genetic Testing Forecast
10.2.2 Canada Market Pan-cancer Genetic Testing Forecast
10.2.3 Mexico Market Pan-cancer Genetic Testing Forecast
10.2.4 Brazil Market Pan-cancer Genetic Testing Forecast
10.3 APAC Pan-cancer Genetic Testing Forecast by Region (2027-2032)
10.3.1 China Pan-cancer Genetic Testing Market Forecast
10.3.2 Japan Market Pan-cancer Genetic Testing Forecast
10.3.3 Korea Market Pan-cancer Genetic Testing Forecast
10.3.4 Southeast Asia Market Pan-cancer Genetic Testing Forecast
10.3.5 India Market Pan-cancer Genetic Testing Forecast
10.3.6 Australia Market Pan-cancer Genetic Testing Forecast
10.4 Europe Pan-cancer Genetic Testing Forecast by Country (2027-2032)
10.4.1 Germany Market Pan-cancer Genetic Testing Forecast
10.4.2 France Market Pan-cancer Genetic Testing Forecast
10.4.3 UK Market Pan-cancer Genetic Testing Forecast
10.4.4 Italy Market Pan-cancer Genetic Testing Forecast
10.4.5 Russia Market Pan-cancer Genetic Testing Forecast
10.5 Middle East & Africa Pan-cancer Genetic Testing Forecast by Region (2027-2032)
10.5.1 Egypt Market Pan-cancer Genetic Testing Forecast
10.5.2 South Africa Market Pan-cancer Genetic Testing Forecast
10.5.3 Israel Market Pan-cancer Genetic Testing Forecast
10.5.4 Turkey Market Pan-cancer Genetic Testing Forecast
10.6 Global Pan-cancer Genetic Testing Forecast by Type (2027-2032)
10.7 Global Pan-cancer Genetic Testing Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Pan-cancer Genetic Testing Forecast
11 KEY PLAYERS ANALYSIS
11.1 Roche
11.1.1 Roche Company Information
11.1.2 Roche Pan-cancer Genetic Testing Product Offered
11.1.3 Roche Pan-cancer Genetic Testing Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Roche Main Business Overview
11.1.5 Roche Latest Developments
11.2 Guardant Health
11.2.1 Guardant Health Company Information
11.2.2 Guardant Health Pan-cancer Genetic Testing Product Offered
11.2.3 Guardant Health Pan-cancer Genetic Testing Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Guardant Health Main Business Overview
11.2.5 Guardant Health Latest Developments
11.3 Caris Life Sciences
11.3.1 Caris Life Sciences Company Information
11.3.2 Caris Life Sciences Pan-cancer Genetic Testing Product Offered
11.3.3 Caris Life Sciences Pan-cancer Genetic Testing Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Caris Life Sciences Main Business Overview
11.3.5 Caris Life Sciences Latest Developments
11.4 Tempus AI
11.4.1 Tempus AI Company Information
11.4.2 Tempus AI Pan-cancer Genetic Testing Product Offered
11.4.3 Tempus AI Pan-cancer Genetic Testing Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Tempus AI Main Business Overview
11.4.5 Tempus AI Latest Developments
11.5 Labcorp
11.5.1 Labcorp Company Information
11.5.2 Labcorp Pan-cancer Genetic Testing Product Offered
11.5.3 Labcorp Pan-cancer Genetic Testing Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Labcorp Main Business Overview
11.5.5 Labcorp Latest Developments
11.6 NeoGenomics
11.6.1 NeoGenomics Company Information
11.6.2 NeoGenomics Pan-cancer Genetic Testing Product Offered
11.6.3 NeoGenomics Pan-cancer Genetic Testing Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 NeoGenomics Main Business Overview
11.6.5 NeoGenomics Latest Developments
11.7 Exact Sciences
11.7.1 Exact Sciences Company Information
11.7.2 Exact Sciences Pan-cancer Genetic Testing Product Offered
11.7.3 Exact Sciences Pan-cancer Genetic Testing Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Exact Sciences Main Business Overview
11.7.5 Exact Sciences Latest Developments
11.8 Personalis
11.8.1 Personalis Company Information
11.8.2 Personalis Pan-cancer Genetic Testing Product Offered
11.8.3 Personalis Pan-cancer Genetic Testing Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Personalis Main Business Overview
11.8.5 Personalis Latest Developments
11.9 Illumina
11.9.1 Illumina Company Information
11.9.2 Illumina Pan-cancer Genetic Testing Product Offered
11.9.3 Illumina Pan-cancer Genetic Testing Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Illumina Main Business Overview
11.9.5 Illumina Latest Developments
11.10 Thermo Fisher Scientific
11.10.1 Thermo Fisher Scientific Company Information
11.10.2 Thermo Fisher Scientific Pan-cancer Genetic Testing Product Offered
11.10.3 Thermo Fisher Scientific Pan-cancer Genetic Testing Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Thermo Fisher Scientific Main Business Overview
11.10.5 Thermo Fisher Scientific Latest Developments
11.11 QIAGEN
11.11.1 QIAGEN Company Information
11.11.2 QIAGEN Pan-cancer Genetic Testing Product Offered
11.11.3 QIAGEN Pan-cancer Genetic Testing Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 QIAGEN Main Business Overview
11.11.5 QIAGEN Latest Developments
11.12 Agilent Technologies
11.12.1 Agilent Technologies Company Information
11.12.2 Agilent Technologies Pan-cancer Genetic Testing Product Offered
11.12.3 Agilent Technologies Pan-cancer Genetic Testing Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 Agilent Technologies Main Business Overview
11.12.5 Agilent Technologies Latest Developments
11.13 SOPHiA GENETICS
11.13.1 SOPHiA GENETICS Company Information
11.13.2 SOPHiA GENETICS Pan-cancer Genetic Testing Product Offered
11.13.3 SOPHiA GENETICS Pan-cancer Genetic Testing Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 SOPHiA GENETICS Main Business Overview
11.13.5 SOPHiA GENETICS Latest Developments
11.14 Sysmex
11.14.1 Sysmex Company Information
11.14.2 Sysmex Pan-cancer Genetic Testing Product Offered
11.14.3 Sysmex Pan-cancer Genetic Testing Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 Sysmex Main Business Overview
11.14.5 Sysmex Latest Developments
11.15 Burning Rock Biotech
11.15.1 Burning Rock Biotech Company Information
11.15.2 Burning Rock Biotech Pan-cancer Genetic Testing Product Offered
11.15.3 Burning Rock Biotech Pan-cancer Genetic Testing Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Burning Rock Biotech Main Business Overview
11.15.5 Burning Rock Biotech Latest Developments
11.16 Genetron Health
11.16.1 Genetron Health Company Information
11.16.2 Genetron Health Pan-cancer Genetic Testing Product Offered
11.16.3 Genetron Health Pan-cancer Genetic Testing Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 Genetron Health Main Business Overview
11.16.5 Genetron Health Latest Developments
11.17 Geneseeq
11.17.1 Geneseeq Company Information
11.17.2 Geneseeq Pan-cancer Genetic Testing Product Offered
11.17.3 Geneseeq Pan-cancer Genetic Testing Revenue, Gross Margin and Market Share (2021-2026)
11.17.4 Geneseeq Main Business Overview
11.17.5 Geneseeq Latest Developments
11.18 BGI Genomics
11.18.1 BGI Genomics Company Information
11.18.2 BGI Genomics Pan-cancer Genetic Testing Product Offered
11.18.3 BGI Genomics Pan-cancer Genetic Testing Revenue, Gross Margin and Market Share (2021-2026)
11.18.4 BGI Genomics Main Business Overview
11.18.5 BGI Genomics Latest Developments
11.19 Amoy Diagnostics
11.19.1 Amoy Diagnostics Company Information
11.19.2 Amoy Diagnostics Pan-cancer Genetic Testing Product Offered
11.19.3 Amoy Diagnostics Pan-cancer Genetic Testing Revenue, Gross Margin and Market Share (2021-2026)
11.19.4 Amoy Diagnostics Main Business Overview
11.19.5 Amoy Diagnostics Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Pan-cancer Genetic Testing Market Size (2021-2032)
2.1.2 Pan-cancer Genetic Testing Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Pan-cancer Genetic Testing by Country/Region (2021, 2025 & 2032)
2.2 Pan-cancer Genetic Testing Segment by Type
2.2.1 Tissue-based Testing
2.2.2 Liquid Biopsy Testing
2.2.3 Other
2.2.4 Pan-cancer Genetic Testing Market Size by Type
2.2.4.1 Pan-cancer Genetic Testing Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.4.2 Global Pan-cancer Genetic Testing Market Size Market Share by Type (2021-2026)
2.3 Pan-cancer Genetic Testing Segment by Testing Scope
2.3.1 Medium Panels (50–199 Genes)
2.3.2 Large Panels (200–599 Genes)
2.3.3 Extended Panels (600–999 Genes)
2.3.4 Other
2.3.5 Pan-cancer Genetic Testing Market Size by Testing Scope
2.3.5.1 Pan-cancer Genetic Testing Market Size CAGR by Testing Scope (2021 VS 2025 VS 2032)
2.3.5.2 Global Pan-cancer Genetic Testing Market Size Market Share by Testing Scope (2021-2026)
2.4 Pan-cancer Genetic Testing Segment by Technology
2.4.1 Targeted NGS
2.4.2 Whole-exome Sequencing
2.4.3 Whole-transcriptome Sequencing
2.4.4 Other
2.4.5 Pan-cancer Genetic Testing Market Size by Technology
2.4.5.1 Pan-cancer Genetic Testing Market Size CAGR by Technology (2021 VS 2025 VS 2032)
2.4.5.2 Global Pan-cancer Genetic Testing Market Size Market Share by Technology (2021-2026)
2.5 Pan-cancer Genetic Testing Segment by Application
2.5.1 Hospitals and Cancer Centers
2.5.2 Independent Clinical Laboratories
2.5.3 Other
2.5.4 Pan-cancer Genetic Testing Market Size by Application
2.5.4.1 Pan-cancer Genetic Testing Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.4.2 Global Pan-cancer Genetic Testing Market Size Market Share by Application (2021-2026)
3 PAN-CANCER GENETIC TESTING MARKET SIZE BY PLAYER
3.1 Pan-cancer Genetic Testing Market Size Market Share by Player
3.1.1 Global Pan-cancer Genetic Testing Revenue by Player (2021-2026)
3.1.2 Global Pan-cancer Genetic Testing Revenue Market Share by Player (2021-2026)
3.2 Global Pan-cancer Genetic Testing Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 PAN-CANCER GENETIC TESTING BY REGION
4.1 Pan-cancer Genetic Testing Market Size by Region (2021-2026)
4.2 Global Pan-cancer Genetic Testing Annual Revenue by Country/Region (2021-2026)
4.3 Americas Pan-cancer Genetic Testing Market Size Growth (2021-2026)
4.4 APAC Pan-cancer Genetic Testing Market Size Growth (2021-2026)
4.5 Europe Pan-cancer Genetic Testing Market Size Growth (2021-2026)
4.6 Middle East & Africa Pan-cancer Genetic Testing Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Pan-cancer Genetic Testing Market Size by Country (2021-2026)
5.2 Americas Pan-cancer Genetic Testing Market Size by Type (2021-2026)
5.3 Americas Pan-cancer Genetic Testing Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Pan-cancer Genetic Testing Market Size by Region (2021-2026)
6.2 APAC Pan-cancer Genetic Testing Market Size by Type (2021-2026)
6.3 APAC Pan-cancer Genetic Testing Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Pan-cancer Genetic Testing Market Size by Country (2021-2026)
7.2 Europe Pan-cancer Genetic Testing Market Size by Type (2021-2026)
7.3 Europe Pan-cancer Genetic Testing Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Pan-cancer Genetic Testing by Region (2021-2026)
8.2 Middle East & Africa Pan-cancer Genetic Testing Market Size by Type (2021-2026)
8.3 Middle East & Africa Pan-cancer Genetic Testing Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL PAN-CANCER GENETIC TESTING MARKET FORECAST
10.1 Global Pan-cancer Genetic Testing Forecast by Region (2027-2032)
10.1.1 Global Pan-cancer Genetic Testing Forecast by Region (2027-2032)
10.1.2 Americas Pan-cancer Genetic Testing Forecast
10.1.3 APAC Pan-cancer Genetic Testing Forecast
10.1.4 Europe Pan-cancer Genetic Testing Forecast
10.1.5 Middle East & Africa Pan-cancer Genetic Testing Forecast
10.2 Americas Pan-cancer Genetic Testing Forecast by Country (2027-2032)
10.2.1 United States Market Pan-cancer Genetic Testing Forecast
10.2.2 Canada Market Pan-cancer Genetic Testing Forecast
10.2.3 Mexico Market Pan-cancer Genetic Testing Forecast
10.2.4 Brazil Market Pan-cancer Genetic Testing Forecast
10.3 APAC Pan-cancer Genetic Testing Forecast by Region (2027-2032)
10.3.1 China Pan-cancer Genetic Testing Market Forecast
10.3.2 Japan Market Pan-cancer Genetic Testing Forecast
10.3.3 Korea Market Pan-cancer Genetic Testing Forecast
10.3.4 Southeast Asia Market Pan-cancer Genetic Testing Forecast
10.3.5 India Market Pan-cancer Genetic Testing Forecast
10.3.6 Australia Market Pan-cancer Genetic Testing Forecast
10.4 Europe Pan-cancer Genetic Testing Forecast by Country (2027-2032)
10.4.1 Germany Market Pan-cancer Genetic Testing Forecast
10.4.2 France Market Pan-cancer Genetic Testing Forecast
10.4.3 UK Market Pan-cancer Genetic Testing Forecast
10.4.4 Italy Market Pan-cancer Genetic Testing Forecast
10.4.5 Russia Market Pan-cancer Genetic Testing Forecast
10.5 Middle East & Africa Pan-cancer Genetic Testing Forecast by Region (2027-2032)
10.5.1 Egypt Market Pan-cancer Genetic Testing Forecast
10.5.2 South Africa Market Pan-cancer Genetic Testing Forecast
10.5.3 Israel Market Pan-cancer Genetic Testing Forecast
10.5.4 Turkey Market Pan-cancer Genetic Testing Forecast
10.6 Global Pan-cancer Genetic Testing Forecast by Type (2027-2032)
10.7 Global Pan-cancer Genetic Testing Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Pan-cancer Genetic Testing Forecast
11 KEY PLAYERS ANALYSIS
11.1 Roche
11.1.1 Roche Company Information
11.1.2 Roche Pan-cancer Genetic Testing Product Offered
11.1.3 Roche Pan-cancer Genetic Testing Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Roche Main Business Overview
11.1.5 Roche Latest Developments
11.2 Guardant Health
11.2.1 Guardant Health Company Information
11.2.2 Guardant Health Pan-cancer Genetic Testing Product Offered
11.2.3 Guardant Health Pan-cancer Genetic Testing Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Guardant Health Main Business Overview
11.2.5 Guardant Health Latest Developments
11.3 Caris Life Sciences
11.3.1 Caris Life Sciences Company Information
11.3.2 Caris Life Sciences Pan-cancer Genetic Testing Product Offered
11.3.3 Caris Life Sciences Pan-cancer Genetic Testing Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Caris Life Sciences Main Business Overview
11.3.5 Caris Life Sciences Latest Developments
11.4 Tempus AI
11.4.1 Tempus AI Company Information
11.4.2 Tempus AI Pan-cancer Genetic Testing Product Offered
11.4.3 Tempus AI Pan-cancer Genetic Testing Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Tempus AI Main Business Overview
11.4.5 Tempus AI Latest Developments
11.5 Labcorp
11.5.1 Labcorp Company Information
11.5.2 Labcorp Pan-cancer Genetic Testing Product Offered
11.5.3 Labcorp Pan-cancer Genetic Testing Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Labcorp Main Business Overview
11.5.5 Labcorp Latest Developments
11.6 NeoGenomics
11.6.1 NeoGenomics Company Information
11.6.2 NeoGenomics Pan-cancer Genetic Testing Product Offered
11.6.3 NeoGenomics Pan-cancer Genetic Testing Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 NeoGenomics Main Business Overview
11.6.5 NeoGenomics Latest Developments
11.7 Exact Sciences
11.7.1 Exact Sciences Company Information
11.7.2 Exact Sciences Pan-cancer Genetic Testing Product Offered
11.7.3 Exact Sciences Pan-cancer Genetic Testing Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Exact Sciences Main Business Overview
11.7.5 Exact Sciences Latest Developments
11.8 Personalis
11.8.1 Personalis Company Information
11.8.2 Personalis Pan-cancer Genetic Testing Product Offered
11.8.3 Personalis Pan-cancer Genetic Testing Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Personalis Main Business Overview
11.8.5 Personalis Latest Developments
11.9 Illumina
11.9.1 Illumina Company Information
11.9.2 Illumina Pan-cancer Genetic Testing Product Offered
11.9.3 Illumina Pan-cancer Genetic Testing Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Illumina Main Business Overview
11.9.5 Illumina Latest Developments
11.10 Thermo Fisher Scientific
11.10.1 Thermo Fisher Scientific Company Information
11.10.2 Thermo Fisher Scientific Pan-cancer Genetic Testing Product Offered
11.10.3 Thermo Fisher Scientific Pan-cancer Genetic Testing Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Thermo Fisher Scientific Main Business Overview
11.10.5 Thermo Fisher Scientific Latest Developments
11.11 QIAGEN
11.11.1 QIAGEN Company Information
11.11.2 QIAGEN Pan-cancer Genetic Testing Product Offered
11.11.3 QIAGEN Pan-cancer Genetic Testing Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 QIAGEN Main Business Overview
11.11.5 QIAGEN Latest Developments
11.12 Agilent Technologies
11.12.1 Agilent Technologies Company Information
11.12.2 Agilent Technologies Pan-cancer Genetic Testing Product Offered
11.12.3 Agilent Technologies Pan-cancer Genetic Testing Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 Agilent Technologies Main Business Overview
11.12.5 Agilent Technologies Latest Developments
11.13 SOPHiA GENETICS
11.13.1 SOPHiA GENETICS Company Information
11.13.2 SOPHiA GENETICS Pan-cancer Genetic Testing Product Offered
11.13.3 SOPHiA GENETICS Pan-cancer Genetic Testing Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 SOPHiA GENETICS Main Business Overview
11.13.5 SOPHiA GENETICS Latest Developments
11.14 Sysmex
11.14.1 Sysmex Company Information
11.14.2 Sysmex Pan-cancer Genetic Testing Product Offered
11.14.3 Sysmex Pan-cancer Genetic Testing Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 Sysmex Main Business Overview
11.14.5 Sysmex Latest Developments
11.15 Burning Rock Biotech
11.15.1 Burning Rock Biotech Company Information
11.15.2 Burning Rock Biotech Pan-cancer Genetic Testing Product Offered
11.15.3 Burning Rock Biotech Pan-cancer Genetic Testing Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Burning Rock Biotech Main Business Overview
11.15.5 Burning Rock Biotech Latest Developments
11.16 Genetron Health
11.16.1 Genetron Health Company Information
11.16.2 Genetron Health Pan-cancer Genetic Testing Product Offered
11.16.3 Genetron Health Pan-cancer Genetic Testing Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 Genetron Health Main Business Overview
11.16.5 Genetron Health Latest Developments
11.17 Geneseeq
11.17.1 Geneseeq Company Information
11.17.2 Geneseeq Pan-cancer Genetic Testing Product Offered
11.17.3 Geneseeq Pan-cancer Genetic Testing Revenue, Gross Margin and Market Share (2021-2026)
11.17.4 Geneseeq Main Business Overview
11.17.5 Geneseeq Latest Developments
11.18 BGI Genomics
11.18.1 BGI Genomics Company Information
11.18.2 BGI Genomics Pan-cancer Genetic Testing Product Offered
11.18.3 BGI Genomics Pan-cancer Genetic Testing Revenue, Gross Margin and Market Share (2021-2026)
11.18.4 BGI Genomics Main Business Overview
11.18.5 BGI Genomics Latest Developments
11.19 Amoy Diagnostics
11.19.1 Amoy Diagnostics Company Information
11.19.2 Amoy Diagnostics Pan-cancer Genetic Testing Product Offered
11.19.3 Amoy Diagnostics Pan-cancer Genetic Testing Revenue, Gross Margin and Market Share (2021-2026)
11.19.4 Amoy Diagnostics Main Business Overview
11.19.5 Amoy Diagnostics Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Pan-cancer Genetic Testing Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Pan-cancer Genetic Testing Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Tissue-based Testing
Table 4. Major Players of Liquid Biopsy Testing
Table 5. Major Players of Other
Table 6. Pan-cancer Genetic Testing Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 7. Global Pan-cancer Genetic Testing Market Size by Type (2021-2026) & ($ millions)
Table 8. Global Pan-cancer Genetic Testing Market Size Market Share by Type (2021-2026)
Table 9. Major Players of Medium Panels (50–199 Genes)
Table 10. Major Players of Large Panels (200–599 Genes)
Table 11. Major Players of Extended Panels (600–999 Genes)
Table 12. Major Players of Other
Table 13. Pan-cancer Genetic Testing Market Size CAGR by Testing Scope (2021 VS 2025 VS 2032) & ($ millions)
Table 14. Global Pan-cancer Genetic Testing Market Size by Testing Scope (2021-2026) & ($ millions)
Table 15. Global Pan-cancer Genetic Testing Market Size Market Share by Testing Scope (2021-2026)
Table 16. Major Players of Targeted NGS
Table 17. Major Players of Whole-exome Sequencing
Table 18. Major Players of Whole-transcriptome Sequencing
Table 19. Major Players of Other
Table 20. Pan-cancer Genetic Testing Market Size CAGR by Technology (2021 VS 2025 VS 2032) & ($ millions)
Table 21. Global Pan-cancer Genetic Testing Market Size by Technology (2021-2026) & ($ millions)
Table 22. Global Pan-cancer Genetic Testing Market Size Market Share by Technology (2021-2026)
Table 23. Pan-cancer Genetic Testing Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 24. Global Pan-cancer Genetic Testing Market Size by Application (2021-2026) & ($ millions)
Table 25. Global Pan-cancer Genetic Testing Market Size Market Share by Application (2021-2026)
Table 26. Global Pan-cancer Genetic Testing Revenue by Player (2021-2026) & ($ millions)
Table 27. Global Pan-cancer Genetic Testing Revenue Market Share by Player (2021-2026)
Table 28. Pan-cancer Genetic Testing Key Players Head office and Products Offered
Table 29. Pan-cancer Genetic Testing Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 30. New Products and Potential Entrants
Table 31. Mergers & Acquisitions, Expansion
Table 32. Global Pan-cancer Genetic Testing Market Size by Region (2021-2026) & ($ millions)
Table 33. Global Pan-cancer Genetic Testing Market Size Market Share by Region (2021-2026)
Table 34. Global Pan-cancer Genetic Testing Revenue by Country/Region (2021-2026) & ($ millions)
Table 35. Global Pan-cancer Genetic Testing Revenue Market Share by Country/Region (2021-2026)
Table 36. Americas Pan-cancer Genetic Testing Market Size by Country (2021-2026) & ($ millions)
Table 37. Americas Pan-cancer Genetic Testing Market Size Market Share by Country (2021-2026)
Table 38. Americas Pan-cancer Genetic Testing Market Size by Type (2021-2026) & ($ millions)
Table 39. Americas Pan-cancer Genetic Testing Market Size Market Share by Type (2021-2026)
Table 40. Americas Pan-cancer Genetic Testing Market Size by Application (2021-2026) & ($ millions)
Table 41. Americas Pan-cancer Genetic Testing Market Size Market Share by Application (2021-2026)
Table 42. APAC Pan-cancer Genetic Testing Market Size by Region (2021-2026) & ($ millions)
Table 43. APAC Pan-cancer Genetic Testing Market Size Market Share by Region (2021-2026)
Table 44. APAC Pan-cancer Genetic Testing Market Size by Type (2021-2026) & ($ millions)
Table 45. APAC Pan-cancer Genetic Testing Market Size by Application (2021-2026) & ($ millions)
Table 46. Europe Pan-cancer Genetic Testing Market Size by Country (2021-2026) & ($ millions)
Table 47. Europe Pan-cancer Genetic Testing Market Size Market Share by Country (2021-2026)
Table 48. Europe Pan-cancer Genetic Testing Market Size by Type (2021-2026) & ($ millions)
Table 49. Europe Pan-cancer Genetic Testing Market Size by Application (2021-2026) & ($ millions)
Table 50. Middle East & Africa Pan-cancer Genetic Testing Market Size by Region (2021-2026) & ($ millions)
Table 51. Middle East & Africa Pan-cancer Genetic Testing Market Size by Type (2021-2026) & ($ millions)
Table 52. Middle East & Africa Pan-cancer Genetic Testing Market Size by Application (2021-2026) & ($ millions)
Table 53. Key Market Drivers & Growth Opportunities of Pan-cancer Genetic Testing
Table 54. Key Market Challenges & Risks of Pan-cancer Genetic Testing
Table 55. Key Industry Trends of Pan-cancer Genetic Testing
Table 56. Global Pan-cancer Genetic Testing Market Size Forecast by Region (2027-2032) & ($ millions)
Table 57. Global Pan-cancer Genetic Testing Market Size Market Share Forecast by Region (2027-2032)
Table 58. Global Pan-cancer Genetic Testing Market Size Forecast by Type (2027-2032) & ($ millions)
Table 59. Global Pan-cancer Genetic Testing Market Size Forecast by Application (2027-2032) & ($ millions)
Table 60. Roche Details, Company Type, Pan-cancer Genetic Testing Area Served and Its Competitors
Table 61. Roche Pan-cancer Genetic Testing Product Offered
Table 62. Roche Pan-cancer Genetic Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 63. Roche Main Business
Table 64. Roche Latest Developments
Table 65. Guardant Health Details, Company Type, Pan-cancer Genetic Testing Area Served and Its Competitors
Table 66. Guardant Health Pan-cancer Genetic Testing Product Offered
Table 67. Guardant Health Pan-cancer Genetic Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 68. Guardant Health Main Business
Table 69. Guardant Health Latest Developments
Table 70. Caris Life Sciences Details, Company Type, Pan-cancer Genetic Testing Area Served and Its Competitors
Table 71. Caris Life Sciences Pan-cancer Genetic Testing Product Offered
Table 72. Caris Life Sciences Pan-cancer Genetic Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 73. Caris Life Sciences Main Business
Table 74. Caris Life Sciences Latest Developments
Table 75. Tempus AI Details, Company Type, Pan-cancer Genetic Testing Area Served and Its Competitors
Table 76. Tempus AI Pan-cancer Genetic Testing Product Offered
Table 77. Tempus AI Pan-cancer Genetic Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 78. Tempus AI Main Business
Table 79. Tempus AI Latest Developments
Table 80. Labcorp Details, Company Type, Pan-cancer Genetic Testing Area Served and Its Competitors
Table 81. Labcorp Pan-cancer Genetic Testing Product Offered
Table 82. Labcorp Pan-cancer Genetic Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 83. Labcorp Main Business
Table 84. Labcorp Latest Developments
Table 85. NeoGenomics Details, Company Type, Pan-cancer Genetic Testing Area Served and Its Competitors
Table 86. NeoGenomics Pan-cancer Genetic Testing Product Offered
Table 87. NeoGenomics Pan-cancer Genetic Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 88. NeoGenomics Main Business
Table 89. NeoGenomics Latest Developments
Table 90. Exact Sciences Details, Company Type, Pan-cancer Genetic Testing Area Served and Its Competitors
Table 91. Exact Sciences Pan-cancer Genetic Testing Product Offered
Table 92. Exact Sciences Pan-cancer Genetic Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 93. Exact Sciences Main Business
Table 94. Exact Sciences Latest Developments
Table 95. Personalis Details, Company Type, Pan-cancer Genetic Testing Area Served and Its Competitors
Table 96. Personalis Pan-cancer Genetic Testing Product Offered
Table 97. Personalis Pan-cancer Genetic Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 98. Personalis Main Business
Table 99. Personalis Latest Developments
Table 100. Illumina Details, Company Type, Pan-cancer Genetic Testing Area Served and Its Competitors
Table 101. Illumina Pan-cancer Genetic Testing Product Offered
Table 102. Illumina Pan-cancer Genetic Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 103. Illumina Main Business
Table 104. Illumina Latest Developments
Table 105. Thermo Fisher Scientific Details, Company Type, Pan-cancer Genetic Testing Area Served and Its Competitors
Table 106. Thermo Fisher Scientific Pan-cancer Genetic Testing Product Offered
Table 107. Thermo Fisher Scientific Pan-cancer Genetic Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 108. Thermo Fisher Scientific Main Business
Table 109. Thermo Fisher Scientific Latest Developments
Table 110. QIAGEN Details, Company Type, Pan-cancer Genetic Testing Area Served and Its Competitors
Table 111. QIAGEN Pan-cancer Genetic Testing Product Offered
Table 112. QIAGEN Pan-cancer Genetic Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 113. QIAGEN Main Business
Table 114. QIAGEN Latest Developments
Table 115. Agilent Technologies Details, Company Type, Pan-cancer Genetic Testing Area Served and Its Competitors
Table 116. Agilent Technologies Pan-cancer Genetic Testing Product Offered
Table 117. Agilent Technologies Pan-cancer Genetic Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 118. Agilent Technologies Main Business
Table 119. Agilent Technologies Latest Developments
Table 120. SOPHiA GENETICS Details, Company Type, Pan-cancer Genetic Testing Area Served and Its Competitors
Table 121. SOPHiA GENETICS Pan-cancer Genetic Testing Product Offered
Table 122. SOPHiA GENETICS Pan-cancer Genetic Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 123. SOPHiA GENETICS Main Business
Table 124. SOPHiA GENETICS Latest Developments
Table 125. Sysmex Details, Company Type, Pan-cancer Genetic Testing Area Served and Its Competitors
Table 126. Sysmex Pan-cancer Genetic Testing Product Offered
Table 127. Sysmex Pan-cancer Genetic Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 128. Sysmex Main Business
Table 129. Sysmex Latest Developments
Table 130. Burning Rock Biotech Details, Company Type, Pan-cancer Genetic Testing Area Served and Its Competitors
Table 131. Burning Rock Biotech Pan-cancer Genetic Testing Product Offered
Table 132. Burning Rock Biotech Pan-cancer Genetic Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 133. Burning Rock Biotech Main Business
Table 134. Burning Rock Biotech Latest Developments
Table 135. Genetron Health Details, Company Type, Pan-cancer Genetic Testing Area Served and Its Competitors
Table 136. Genetron Health Pan-cancer Genetic Testing Product Offered
Table 137. Genetron Health Pan-cancer Genetic Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 138. Genetron Health Main Business
Table 139. Genetron Health Latest Developments
Table 140. Geneseeq Details, Company Type, Pan-cancer Genetic Testing Area Served and Its Competitors
Table 141. Geneseeq Pan-cancer Genetic Testing Product Offered
Table 142. Geneseeq Pan-cancer Genetic Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 143. Geneseeq Main Business
Table 144. Geneseeq Latest Developments
Table 145. BGI Genomics Details, Company Type, Pan-cancer Genetic Testing Area Served and Its Competitors
Table 146. BGI Genomics Pan-cancer Genetic Testing Product Offered
Table 147. BGI Genomics Pan-cancer Genetic Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 148. BGI Genomics Main Business
Table 149. BGI Genomics Latest Developments
Table 150. Amoy Diagnostics Details, Company Type, Pan-cancer Genetic Testing Area Served and Its Competitors
Table 151. Amoy Diagnostics Pan-cancer Genetic Testing Product Offered
Table 152. Amoy Diagnostics Pan-cancer Genetic Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 153. Amoy Diagnostics Main Business
Table 154. Amoy Diagnostics Latest Developments
Table 1. Pan-cancer Genetic Testing Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Pan-cancer Genetic Testing Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Tissue-based Testing
Table 4. Major Players of Liquid Biopsy Testing
Table 5. Major Players of Other
Table 6. Pan-cancer Genetic Testing Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 7. Global Pan-cancer Genetic Testing Market Size by Type (2021-2026) & ($ millions)
Table 8. Global Pan-cancer Genetic Testing Market Size Market Share by Type (2021-2026)
Table 9. Major Players of Medium Panels (50–199 Genes)
Table 10. Major Players of Large Panels (200–599 Genes)
Table 11. Major Players of Extended Panels (600–999 Genes)
Table 12. Major Players of Other
Table 13. Pan-cancer Genetic Testing Market Size CAGR by Testing Scope (2021 VS 2025 VS 2032) & ($ millions)
Table 14. Global Pan-cancer Genetic Testing Market Size by Testing Scope (2021-2026) & ($ millions)
Table 15. Global Pan-cancer Genetic Testing Market Size Market Share by Testing Scope (2021-2026)
Table 16. Major Players of Targeted NGS
Table 17. Major Players of Whole-exome Sequencing
Table 18. Major Players of Whole-transcriptome Sequencing
Table 19. Major Players of Other
Table 20. Pan-cancer Genetic Testing Market Size CAGR by Technology (2021 VS 2025 VS 2032) & ($ millions)
Table 21. Global Pan-cancer Genetic Testing Market Size by Technology (2021-2026) & ($ millions)
Table 22. Global Pan-cancer Genetic Testing Market Size Market Share by Technology (2021-2026)
Table 23. Pan-cancer Genetic Testing Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 24. Global Pan-cancer Genetic Testing Market Size by Application (2021-2026) & ($ millions)
Table 25. Global Pan-cancer Genetic Testing Market Size Market Share by Application (2021-2026)
Table 26. Global Pan-cancer Genetic Testing Revenue by Player (2021-2026) & ($ millions)
Table 27. Global Pan-cancer Genetic Testing Revenue Market Share by Player (2021-2026)
Table 28. Pan-cancer Genetic Testing Key Players Head office and Products Offered
Table 29. Pan-cancer Genetic Testing Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 30. New Products and Potential Entrants
Table 31. Mergers & Acquisitions, Expansion
Table 32. Global Pan-cancer Genetic Testing Market Size by Region (2021-2026) & ($ millions)
Table 33. Global Pan-cancer Genetic Testing Market Size Market Share by Region (2021-2026)
Table 34. Global Pan-cancer Genetic Testing Revenue by Country/Region (2021-2026) & ($ millions)
Table 35. Global Pan-cancer Genetic Testing Revenue Market Share by Country/Region (2021-2026)
Table 36. Americas Pan-cancer Genetic Testing Market Size by Country (2021-2026) & ($ millions)
Table 37. Americas Pan-cancer Genetic Testing Market Size Market Share by Country (2021-2026)
Table 38. Americas Pan-cancer Genetic Testing Market Size by Type (2021-2026) & ($ millions)
Table 39. Americas Pan-cancer Genetic Testing Market Size Market Share by Type (2021-2026)
Table 40. Americas Pan-cancer Genetic Testing Market Size by Application (2021-2026) & ($ millions)
Table 41. Americas Pan-cancer Genetic Testing Market Size Market Share by Application (2021-2026)
Table 42. APAC Pan-cancer Genetic Testing Market Size by Region (2021-2026) & ($ millions)
Table 43. APAC Pan-cancer Genetic Testing Market Size Market Share by Region (2021-2026)
Table 44. APAC Pan-cancer Genetic Testing Market Size by Type (2021-2026) & ($ millions)
Table 45. APAC Pan-cancer Genetic Testing Market Size by Application (2021-2026) & ($ millions)
Table 46. Europe Pan-cancer Genetic Testing Market Size by Country (2021-2026) & ($ millions)
Table 47. Europe Pan-cancer Genetic Testing Market Size Market Share by Country (2021-2026)
Table 48. Europe Pan-cancer Genetic Testing Market Size by Type (2021-2026) & ($ millions)
Table 49. Europe Pan-cancer Genetic Testing Market Size by Application (2021-2026) & ($ millions)
Table 50. Middle East & Africa Pan-cancer Genetic Testing Market Size by Region (2021-2026) & ($ millions)
Table 51. Middle East & Africa Pan-cancer Genetic Testing Market Size by Type (2021-2026) & ($ millions)
Table 52. Middle East & Africa Pan-cancer Genetic Testing Market Size by Application (2021-2026) & ($ millions)
Table 53. Key Market Drivers & Growth Opportunities of Pan-cancer Genetic Testing
Table 54. Key Market Challenges & Risks of Pan-cancer Genetic Testing
Table 55. Key Industry Trends of Pan-cancer Genetic Testing
Table 56. Global Pan-cancer Genetic Testing Market Size Forecast by Region (2027-2032) & ($ millions)
Table 57. Global Pan-cancer Genetic Testing Market Size Market Share Forecast by Region (2027-2032)
Table 58. Global Pan-cancer Genetic Testing Market Size Forecast by Type (2027-2032) & ($ millions)
Table 59. Global Pan-cancer Genetic Testing Market Size Forecast by Application (2027-2032) & ($ millions)
Table 60. Roche Details, Company Type, Pan-cancer Genetic Testing Area Served and Its Competitors
Table 61. Roche Pan-cancer Genetic Testing Product Offered
Table 62. Roche Pan-cancer Genetic Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 63. Roche Main Business
Table 64. Roche Latest Developments
Table 65. Guardant Health Details, Company Type, Pan-cancer Genetic Testing Area Served and Its Competitors
Table 66. Guardant Health Pan-cancer Genetic Testing Product Offered
Table 67. Guardant Health Pan-cancer Genetic Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 68. Guardant Health Main Business
Table 69. Guardant Health Latest Developments
Table 70. Caris Life Sciences Details, Company Type, Pan-cancer Genetic Testing Area Served and Its Competitors
Table 71. Caris Life Sciences Pan-cancer Genetic Testing Product Offered
Table 72. Caris Life Sciences Pan-cancer Genetic Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 73. Caris Life Sciences Main Business
Table 74. Caris Life Sciences Latest Developments
Table 75. Tempus AI Details, Company Type, Pan-cancer Genetic Testing Area Served and Its Competitors
Table 76. Tempus AI Pan-cancer Genetic Testing Product Offered
Table 77. Tempus AI Pan-cancer Genetic Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 78. Tempus AI Main Business
Table 79. Tempus AI Latest Developments
Table 80. Labcorp Details, Company Type, Pan-cancer Genetic Testing Area Served and Its Competitors
Table 81. Labcorp Pan-cancer Genetic Testing Product Offered
Table 82. Labcorp Pan-cancer Genetic Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 83. Labcorp Main Business
Table 84. Labcorp Latest Developments
Table 85. NeoGenomics Details, Company Type, Pan-cancer Genetic Testing Area Served and Its Competitors
Table 86. NeoGenomics Pan-cancer Genetic Testing Product Offered
Table 87. NeoGenomics Pan-cancer Genetic Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 88. NeoGenomics Main Business
Table 89. NeoGenomics Latest Developments
Table 90. Exact Sciences Details, Company Type, Pan-cancer Genetic Testing Area Served and Its Competitors
Table 91. Exact Sciences Pan-cancer Genetic Testing Product Offered
Table 92. Exact Sciences Pan-cancer Genetic Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 93. Exact Sciences Main Business
Table 94. Exact Sciences Latest Developments
Table 95. Personalis Details, Company Type, Pan-cancer Genetic Testing Area Served and Its Competitors
Table 96. Personalis Pan-cancer Genetic Testing Product Offered
Table 97. Personalis Pan-cancer Genetic Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 98. Personalis Main Business
Table 99. Personalis Latest Developments
Table 100. Illumina Details, Company Type, Pan-cancer Genetic Testing Area Served and Its Competitors
Table 101. Illumina Pan-cancer Genetic Testing Product Offered
Table 102. Illumina Pan-cancer Genetic Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 103. Illumina Main Business
Table 104. Illumina Latest Developments
Table 105. Thermo Fisher Scientific Details, Company Type, Pan-cancer Genetic Testing Area Served and Its Competitors
Table 106. Thermo Fisher Scientific Pan-cancer Genetic Testing Product Offered
Table 107. Thermo Fisher Scientific Pan-cancer Genetic Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 108. Thermo Fisher Scientific Main Business
Table 109. Thermo Fisher Scientific Latest Developments
Table 110. QIAGEN Details, Company Type, Pan-cancer Genetic Testing Area Served and Its Competitors
Table 111. QIAGEN Pan-cancer Genetic Testing Product Offered
Table 112. QIAGEN Pan-cancer Genetic Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 113. QIAGEN Main Business
Table 114. QIAGEN Latest Developments
Table 115. Agilent Technologies Details, Company Type, Pan-cancer Genetic Testing Area Served and Its Competitors
Table 116. Agilent Technologies Pan-cancer Genetic Testing Product Offered
Table 117. Agilent Technologies Pan-cancer Genetic Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 118. Agilent Technologies Main Business
Table 119. Agilent Technologies Latest Developments
Table 120. SOPHiA GENETICS Details, Company Type, Pan-cancer Genetic Testing Area Served and Its Competitors
Table 121. SOPHiA GENETICS Pan-cancer Genetic Testing Product Offered
Table 122. SOPHiA GENETICS Pan-cancer Genetic Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 123. SOPHiA GENETICS Main Business
Table 124. SOPHiA GENETICS Latest Developments
Table 125. Sysmex Details, Company Type, Pan-cancer Genetic Testing Area Served and Its Competitors
Table 126. Sysmex Pan-cancer Genetic Testing Product Offered
Table 127. Sysmex Pan-cancer Genetic Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 128. Sysmex Main Business
Table 129. Sysmex Latest Developments
Table 130. Burning Rock Biotech Details, Company Type, Pan-cancer Genetic Testing Area Served and Its Competitors
Table 131. Burning Rock Biotech Pan-cancer Genetic Testing Product Offered
Table 132. Burning Rock Biotech Pan-cancer Genetic Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 133. Burning Rock Biotech Main Business
Table 134. Burning Rock Biotech Latest Developments
Table 135. Genetron Health Details, Company Type, Pan-cancer Genetic Testing Area Served and Its Competitors
Table 136. Genetron Health Pan-cancer Genetic Testing Product Offered
Table 137. Genetron Health Pan-cancer Genetic Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 138. Genetron Health Main Business
Table 139. Genetron Health Latest Developments
Table 140. Geneseeq Details, Company Type, Pan-cancer Genetic Testing Area Served and Its Competitors
Table 141. Geneseeq Pan-cancer Genetic Testing Product Offered
Table 142. Geneseeq Pan-cancer Genetic Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 143. Geneseeq Main Business
Table 144. Geneseeq Latest Developments
Table 145. BGI Genomics Details, Company Type, Pan-cancer Genetic Testing Area Served and Its Competitors
Table 146. BGI Genomics Pan-cancer Genetic Testing Product Offered
Table 147. BGI Genomics Pan-cancer Genetic Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 148. BGI Genomics Main Business
Table 149. BGI Genomics Latest Developments
Table 150. Amoy Diagnostics Details, Company Type, Pan-cancer Genetic Testing Area Served and Its Competitors
Table 151. Amoy Diagnostics Pan-cancer Genetic Testing Product Offered
Table 152. Amoy Diagnostics Pan-cancer Genetic Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 153. Amoy Diagnostics Main Business
Table 154. Amoy Diagnostics Latest Developments
LIST OF FIGURES
Figure 1. Pan-cancer Genetic Testing Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Pan-cancer Genetic Testing Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Pan-cancer Genetic Testing Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Pan-cancer Genetic Testing Sales Market Share by Country/Region (2025)
Figure 8. Pan-cancer Genetic Testing Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Pan-cancer Genetic Testing Market Size Market Share by Type in 2025
Figure 10. Global Pan-cancer Genetic Testing Market Size Market Share by Testing Scope in 2025
Figure 11. Global Pan-cancer Genetic Testing Market Size Market Share by Technology in 2025
Figure 12. Pan-cancer Genetic Testing in Hospitals and Cancer Centers
Figure 13. Global Pan-cancer Genetic Testing Market: Hospitals and Cancer Centers (2021-2026) & ($ millions)
Figure 14. Pan-cancer Genetic Testing in Independent Clinical Laboratories
Figure 15. Global Pan-cancer Genetic Testing Market: Independent Clinical Laboratories (2021-2026) & ($ millions)
Figure 16. Pan-cancer Genetic Testing in Other
Figure 17. Global Pan-cancer Genetic Testing Market: Other (2021-2026) & ($ millions)
Figure 18. Global Pan-cancer Genetic Testing Market Size Market Share by Application in 2025
Figure 19. Global Pan-cancer Genetic Testing Revenue Market Share by Player in 2025
Figure 20. Global Pan-cancer Genetic Testing Market Size Market Share by Region (2021-2026)
Figure 21. Americas Pan-cancer Genetic Testing Market Size 2021-2026 ($ millions)
Figure 22. APAC Pan-cancer Genetic Testing Market Size 2021-2026 ($ millions)
Figure 23. Europe Pan-cancer Genetic Testing Market Size 2021-2026 ($ millions)
Figure 24. Middle East & Africa Pan-cancer Genetic Testing Market Size 2021-2026 ($ millions)
Figure 25. Americas Pan-cancer Genetic Testing Value Market Share by Country in 2025
Figure 26. United States Pan-cancer Genetic Testing Market Size Growth 2021-2026 ($ millions)
Figure 27. Canada Pan-cancer Genetic Testing Market Size Growth 2021-2026 ($ millions)
Figure 28. Mexico Pan-cancer Genetic Testing Market Size Growth 2021-2026 ($ millions)
Figure 29. Brazil Pan-cancer Genetic Testing Market Size Growth 2021-2026 ($ millions)
Figure 30. APAC Pan-cancer Genetic Testing Market Size Market Share by Region in 2025
Figure 31. APAC Pan-cancer Genetic Testing Market Size Market Share by Type (2021-2026)
Figure 32. APAC Pan-cancer Genetic Testing Market Size Market Share by Application (2021-2026)
Figure 33. China Pan-cancer Genetic Testing Market Size Growth 2021-2026 ($ millions)
Figure 34. Japan Pan-cancer Genetic Testing Market Size Growth 2021-2026 ($ millions)
Figure 35. South Korea Pan-cancer Genetic Testing Market Size Growth 2021-2026 ($ millions)
Figure 36. Southeast Asia Pan-cancer Genetic Testing Market Size Growth 2021-2026 ($ millions)
Figure 37. India Pan-cancer Genetic Testing Market Size Growth 2021-2026 ($ millions)
Figure 38. Australia Pan-cancer Genetic Testing Market Size Growth 2021-2026 ($ millions)
Figure 39. Europe Pan-cancer Genetic Testing Market Size Market Share by Country in 2025
Figure 40. Europe Pan-cancer Genetic Testing Market Size Market Share by Type (2021-2026)
Figure 41. Europe Pan-cancer Genetic Testing Market Size Market Share by Application (2021-2026)
Figure 42. Germany Pan-cancer Genetic Testing Market Size Growth 2021-2026 ($ millions)
Figure 43. France Pan-cancer Genetic Testing Market Size Growth 2021-2026 ($ millions)
Figure 44. UK Pan-cancer Genetic Testing Market Size Growth 2021-2026 ($ millions)
Figure 45. Italy Pan-cancer Genetic Testing Market Size Growth 2021-2026 ($ millions)
Figure 46. Russia Pan-cancer Genetic Testing Market Size Growth 2021-2026 ($ millions)
Figure 47. Middle East & Africa Pan-cancer Genetic Testing Market Size Market Share by Region (2021-2026)
Figure 48. Middle East & Africa Pan-cancer Genetic Testing Market Size Market Share by Type (2021-2026)
Figure 49. Middle East & Africa Pan-cancer Genetic Testing Market Size Market Share by Application (2021-2026)
Figure 50. Egypt Pan-cancer Genetic Testing Market Size Growth 2021-2026 ($ millions)
Figure 51. South Africa Pan-cancer Genetic Testing Market Size Growth 2021-2026 ($ millions)
Figure 52. Israel Pan-cancer Genetic Testing Market Size Growth 2021-2026 ($ millions)
Figure 53. Turkey Pan-cancer Genetic Testing Market Size Growth 2021-2026 ($ millions)
Figure 54. GCC Countries Pan-cancer Genetic Testing Market Size Growth 2021-2026 ($ millions)
Figure 55. Americas Pan-cancer Genetic Testing Market Size 2027-2032 ($ millions)
Figure 56. APAC Pan-cancer Genetic Testing Market Size 2027-2032 ($ millions)
Figure 57. Europe Pan-cancer Genetic Testing Market Size 2027-2032 ($ millions)
Figure 58. Middle East & Africa Pan-cancer Genetic Testing Market Size 2027-2032 ($ millions)
Figure 59. United States Pan-cancer Genetic Testing Market Size 2027-2032 ($ millions)
Figure 60. Canada Pan-cancer Genetic Testing Market Size 2027-2032 ($ millions)
Figure 61. Mexico Pan-cancer Genetic Testing Market Size 2027-2032 ($ millions)
Figure 62. Brazil Pan-cancer Genetic Testing Market Size 2027-2032 ($ millions)
Figure 63. China Pan-cancer Genetic Testing Market Size 2027-2032 ($ millions)
Figure 64. Japan Pan-cancer Genetic Testing Market Size 2027-2032 ($ millions)
Figure 65. Korea Pan-cancer Genetic Testing Market Size 2027-2032 ($ millions)
Figure 66. Southeast Asia Pan-cancer Genetic Testing Market Size 2027-2032 ($ millions)
Figure 67. India Pan-cancer Genetic Testing Market Size 2027-2032 ($ millions)
Figure 68. Australia Pan-cancer Genetic Testing Market Size 2027-2032 ($ millions)
Figure 69. Germany Pan-cancer Genetic Testing Market Size 2027-2032 ($ millions)
Figure 70. France Pan-cancer Genetic Testing Market Size 2027-2032 ($ millions)
Figure 71. UK Pan-cancer Genetic Testing Market Size 2027-2032 ($ millions)
Figure 72. Italy Pan-cancer Genetic Testing Market Size 2027-2032 ($ millions)
Figure 73. Russia Pan-cancer Genetic Testing Market Size 2027-2032 ($ millions)
Figure 74. Egypt Pan-cancer Genetic Testing Market Size 2027-2032 ($ millions)
Figure 75. South Africa Pan-cancer Genetic Testing Market Size 2027-2032 ($ millions)
Figure 76. Israel Pan-cancer Genetic Testing Market Size 2027-2032 ($ millions)
Figure 77. Turkey Pan-cancer Genetic Testing Market Size 2027-2032 ($ millions)
Figure 78. Global Pan-cancer Genetic Testing Market Size Market Share Forecast by Type (2027-2032)
Figure 79. Global Pan-cancer Genetic Testing Market Size Market Share Forecast by Application (2027-2032)
Figure 80. GCC Countries Pan-cancer Genetic Testing Market Size 2027-2032 ($ millions)
Figure 1. Pan-cancer Genetic Testing Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Pan-cancer Genetic Testing Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Pan-cancer Genetic Testing Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Pan-cancer Genetic Testing Sales Market Share by Country/Region (2025)
Figure 8. Pan-cancer Genetic Testing Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Pan-cancer Genetic Testing Market Size Market Share by Type in 2025
Figure 10. Global Pan-cancer Genetic Testing Market Size Market Share by Testing Scope in 2025
Figure 11. Global Pan-cancer Genetic Testing Market Size Market Share by Technology in 2025
Figure 12. Pan-cancer Genetic Testing in Hospitals and Cancer Centers
Figure 13. Global Pan-cancer Genetic Testing Market: Hospitals and Cancer Centers (2021-2026) & ($ millions)
Figure 14. Pan-cancer Genetic Testing in Independent Clinical Laboratories
Figure 15. Global Pan-cancer Genetic Testing Market: Independent Clinical Laboratories (2021-2026) & ($ millions)
Figure 16. Pan-cancer Genetic Testing in Other
Figure 17. Global Pan-cancer Genetic Testing Market: Other (2021-2026) & ($ millions)
Figure 18. Global Pan-cancer Genetic Testing Market Size Market Share by Application in 2025
Figure 19. Global Pan-cancer Genetic Testing Revenue Market Share by Player in 2025
Figure 20. Global Pan-cancer Genetic Testing Market Size Market Share by Region (2021-2026)
Figure 21. Americas Pan-cancer Genetic Testing Market Size 2021-2026 ($ millions)
Figure 22. APAC Pan-cancer Genetic Testing Market Size 2021-2026 ($ millions)
Figure 23. Europe Pan-cancer Genetic Testing Market Size 2021-2026 ($ millions)
Figure 24. Middle East & Africa Pan-cancer Genetic Testing Market Size 2021-2026 ($ millions)
Figure 25. Americas Pan-cancer Genetic Testing Value Market Share by Country in 2025
Figure 26. United States Pan-cancer Genetic Testing Market Size Growth 2021-2026 ($ millions)
Figure 27. Canada Pan-cancer Genetic Testing Market Size Growth 2021-2026 ($ millions)
Figure 28. Mexico Pan-cancer Genetic Testing Market Size Growth 2021-2026 ($ millions)
Figure 29. Brazil Pan-cancer Genetic Testing Market Size Growth 2021-2026 ($ millions)
Figure 30. APAC Pan-cancer Genetic Testing Market Size Market Share by Region in 2025
Figure 31. APAC Pan-cancer Genetic Testing Market Size Market Share by Type (2021-2026)
Figure 32. APAC Pan-cancer Genetic Testing Market Size Market Share by Application (2021-2026)
Figure 33. China Pan-cancer Genetic Testing Market Size Growth 2021-2026 ($ millions)
Figure 34. Japan Pan-cancer Genetic Testing Market Size Growth 2021-2026 ($ millions)
Figure 35. South Korea Pan-cancer Genetic Testing Market Size Growth 2021-2026 ($ millions)
Figure 36. Southeast Asia Pan-cancer Genetic Testing Market Size Growth 2021-2026 ($ millions)
Figure 37. India Pan-cancer Genetic Testing Market Size Growth 2021-2026 ($ millions)
Figure 38. Australia Pan-cancer Genetic Testing Market Size Growth 2021-2026 ($ millions)
Figure 39. Europe Pan-cancer Genetic Testing Market Size Market Share by Country in 2025
Figure 40. Europe Pan-cancer Genetic Testing Market Size Market Share by Type (2021-2026)
Figure 41. Europe Pan-cancer Genetic Testing Market Size Market Share by Application (2021-2026)
Figure 42. Germany Pan-cancer Genetic Testing Market Size Growth 2021-2026 ($ millions)
Figure 43. France Pan-cancer Genetic Testing Market Size Growth 2021-2026 ($ millions)
Figure 44. UK Pan-cancer Genetic Testing Market Size Growth 2021-2026 ($ millions)
Figure 45. Italy Pan-cancer Genetic Testing Market Size Growth 2021-2026 ($ millions)
Figure 46. Russia Pan-cancer Genetic Testing Market Size Growth 2021-2026 ($ millions)
Figure 47. Middle East & Africa Pan-cancer Genetic Testing Market Size Market Share by Region (2021-2026)
Figure 48. Middle East & Africa Pan-cancer Genetic Testing Market Size Market Share by Type (2021-2026)
Figure 49. Middle East & Africa Pan-cancer Genetic Testing Market Size Market Share by Application (2021-2026)
Figure 50. Egypt Pan-cancer Genetic Testing Market Size Growth 2021-2026 ($ millions)
Figure 51. South Africa Pan-cancer Genetic Testing Market Size Growth 2021-2026 ($ millions)
Figure 52. Israel Pan-cancer Genetic Testing Market Size Growth 2021-2026 ($ millions)
Figure 53. Turkey Pan-cancer Genetic Testing Market Size Growth 2021-2026 ($ millions)
Figure 54. GCC Countries Pan-cancer Genetic Testing Market Size Growth 2021-2026 ($ millions)
Figure 55. Americas Pan-cancer Genetic Testing Market Size 2027-2032 ($ millions)
Figure 56. APAC Pan-cancer Genetic Testing Market Size 2027-2032 ($ millions)
Figure 57. Europe Pan-cancer Genetic Testing Market Size 2027-2032 ($ millions)
Figure 58. Middle East & Africa Pan-cancer Genetic Testing Market Size 2027-2032 ($ millions)
Figure 59. United States Pan-cancer Genetic Testing Market Size 2027-2032 ($ millions)
Figure 60. Canada Pan-cancer Genetic Testing Market Size 2027-2032 ($ millions)
Figure 61. Mexico Pan-cancer Genetic Testing Market Size 2027-2032 ($ millions)
Figure 62. Brazil Pan-cancer Genetic Testing Market Size 2027-2032 ($ millions)
Figure 63. China Pan-cancer Genetic Testing Market Size 2027-2032 ($ millions)
Figure 64. Japan Pan-cancer Genetic Testing Market Size 2027-2032 ($ millions)
Figure 65. Korea Pan-cancer Genetic Testing Market Size 2027-2032 ($ millions)
Figure 66. Southeast Asia Pan-cancer Genetic Testing Market Size 2027-2032 ($ millions)
Figure 67. India Pan-cancer Genetic Testing Market Size 2027-2032 ($ millions)
Figure 68. Australia Pan-cancer Genetic Testing Market Size 2027-2032 ($ millions)
Figure 69. Germany Pan-cancer Genetic Testing Market Size 2027-2032 ($ millions)
Figure 70. France Pan-cancer Genetic Testing Market Size 2027-2032 ($ millions)
Figure 71. UK Pan-cancer Genetic Testing Market Size 2027-2032 ($ millions)
Figure 72. Italy Pan-cancer Genetic Testing Market Size 2027-2032 ($ millions)
Figure 73. Russia Pan-cancer Genetic Testing Market Size 2027-2032 ($ millions)
Figure 74. Egypt Pan-cancer Genetic Testing Market Size 2027-2032 ($ millions)
Figure 75. South Africa Pan-cancer Genetic Testing Market Size 2027-2032 ($ millions)
Figure 76. Israel Pan-cancer Genetic Testing Market Size 2027-2032 ($ millions)
Figure 77. Turkey Pan-cancer Genetic Testing Market Size 2027-2032 ($ millions)
Figure 78. Global Pan-cancer Genetic Testing Market Size Market Share Forecast by Type (2027-2032)
Figure 79. Global Pan-cancer Genetic Testing Market Size Market Share Forecast by Application (2027-2032)
Figure 80. GCC Countries Pan-cancer Genetic Testing Market Size 2027-2032 ($ millions)
